Daniel Lasanow
Chairman at Polypeptide Laboratories France SAS
Net worth: 261 286 $ as of 30/03/2024
Profile
Daniel Lasanow currently works at Polypeptide Laboratories France SAS, as Chairman from 2017.
Mr. Lasanow also formerly worked at Lonza, Inc., as Production Director, NextPharma Technologies SA (Belgium), as Production Director from 2009 to 2011, UCB-Bioproducts SA, as Production Director, and PolyPeptide Group AG, as Director-Global Operations from 2016 to 2022.
Mr. Lasanow received his graduate degree from Université Catholique de Louvain.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
POLYPEPTIDE GROUP AG
0.02% | 30/12/2022 | 7,767 ( 0.02% ) | 261 286 $ | 30/03/2024 |
Daniel Lasanow active positions
| Companies | Position | Start |
|---|---|---|
Polypeptide Laboratories France SAS
 Polypeptide Laboratories France SAS Chemicals: SpecialtyProcess Industries Part of PolyPeptide Group AG, Polypeptide Laboratories France SAS is a contract manufacturer of organic peptides. The private company is based in Strasbourg, France. | Chairman | 09/04/2017 |
Former positions of Daniel Lasanow
| Companies | Position | End |
|---|---|---|
| POLYPEPTIDE GROUP AG | Chief Operating Officer | 29/11/2022 |
| NextPharma Technologies SA (Belgium) | Corporate Officer/Principal | 31/12/2010 |
UCB-Bioproducts SA
 UCB-Bioproducts SA Miscellaneous Commercial ServicesCommercial Services UCB-Bioproducts is a Belgian based, international Contract Services Company, focusing on custom peptide and peptidomimetics (for pharmaceutical use) process development, regulatory services and manufacturing services along with strong support to customers' clinical trials. UCB-Bioproducts mission is to create value by supporting pharmaceutical players to bring innovative drugs to the market to improve the lives of people. | Corporate Officer/Principal | - |
Lonza, Inc.
 Lonza, Inc. Chemicals: SpecialtyProcess Industries Lonza, Inc. provides chemical ingredient products. The company is headquartered in Allendale, NJ. | Corporate Officer/Principal | - |
Training of Daniel Lasanow
| Université Catholique de Louvain | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| POLYPEPTIDE GROUP AG | Health Technology |
| Private companies | 4 |
|---|---|
Lonza, Inc.
Lonza, Inc. Chemicals: SpecialtyProcess Industries Lonza, Inc. provides chemical ingredient products. The company is headquartered in Allendale, NJ. | Process Industries |
| NextPharma Technologies SA (Belgium) | |
UCB-Bioproducts SA
UCB-Bioproducts SA Miscellaneous Commercial ServicesCommercial Services UCB-Bioproducts is a Belgian based, international Contract Services Company, focusing on custom peptide and peptidomimetics (for pharmaceutical use) process development, regulatory services and manufacturing services along with strong support to customers' clinical trials. UCB-Bioproducts mission is to create value by supporting pharmaceutical players to bring innovative drugs to the market to improve the lives of people. | Commercial Services |
Polypeptide Laboratories France SAS
Polypeptide Laboratories France SAS Chemicals: SpecialtyProcess Industries Part of PolyPeptide Group AG, Polypeptide Laboratories France SAS is a contract manufacturer of organic peptides. The private company is based in Strasbourg, France. | Process Industries |
- Stock Market
- Insiders
- Daniel Lasanow
